Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06531525

Effect of Low Molecular Heparin on Pregnancy Outcome With Protein S Deficiency

To evaluate whether low molecular heparin could improve pregnancy outcomes in pregnancies with protein S deficiency.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–50 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

About this study

This is a parallel-group, multicenter, randomized controlled trial of 48 pregnancies with protein S deficiency in China. Patients are randomized into three groups to receive enoxaparin combined with aspirin, aspirin alone and no intervention. The primary outcome measure is livebirth rate.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Plasma activity levels of PS when not pregnant are below the lower limits of the adult reference values (generally about 60-70% for PS) without the use of warfarin. Or, free protein S antigen levels in the second and third trimesters are less than 30% and less than 24%, respectively
  • Pregnant women who delivered from Aug 1st, 2024 to Oct 15th, 2027
  • One or more family members exhibiting the same symptoms as the patient
  • Past history of early onset thrombosis (age 50 or below)
  • Repeated recurrence of thrombosis
  • Thromboses in unusual sites
  • New onset of thrombosis during current pregnancy or after delivery
  • Patients with diagnosis confirmed by gene analysis Inclusion criteria 1 and 2 must always be met regardless of items of 3-8.
  • Written informed consent

Exclusion criteria

  • Thrombophilia other than Protein S deficiency
  • Antiphospholipid syndrome, systemic lupus erythematosus, platelet abnormalities, vascular disorders, blood flow obstruction, paroxysmal nocturnal hemoglobinuria, malignant tumor and other conditions that tend to cause thrombosis
  • Allergy/hypersensitivity to enoxaparin or aspirin
  • Heparin-associated thrombocytopenia or thrombocytopenia (platelet count<75 × 10^9/L)
  • Organ lesions at risk for bleeding such as acute stomach/bowel ulcers, cerebral hemorrhage, cerebral aneurysm
  • uncontrolled hypertension or Severe hypertension (Systolic Blood Pressure >200mmhg and/or Diastolic Blood Pressure >120mmHg)
  • Severe hepatic failure (INR >1.8)
  • Serum creatinine greater than 80 umol/L (1.3mg/dl) and an abnormal 24 hour urine creatine clearance (<30ml/min)
  • Abnormal uterine cavity on hysterosalpingogram/hysteroscopy

Treatment and study plan

Enoxaparin

Drug

Enoxaparin 4000 IU/day by subcutaneous injection at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.

Other names: lovenox, clexane

Aspirin

Drug

Aspirin 75mg, orally, once daily at the time of randomization and continued until delivery. Dose adjustments were made throughout the study based on symptoms such as bleeding and thrombosis.

Other names: ASA

Primary outcomes

  1. Rate of livebirth

    Time frame: From date of randomization until delivery, assessed up to 42 months

    Incidents of livebirth

Secondary outcomes

  1. Parameters of maternal coagulation-related indicators

    Time frame: From the start of study treatment to 6 weeks post-partum

    D-Dimer in ng/ml, Protein S activity in %

  2. Parameters to assess the safety of low molecular heparin

    Time frame: From the start of study treatment to 6 weeks post-partum

    Maternal platelet count in 10^9/L, Number of haemorrhagic events, Number of cases of skin reactions at injection site

  3. Other incidents of adverse pregnancy outcomes

    Time frame: up to 37 weeks

    early miscarriage (until 12 weeks of gestation), late miscarriage (12-28 weeks of gestation), premature livebirths (28-37 weeks of gestation)

  4. Neonatal Data

    Time frame: after the delivery (an expected average of one month)

    Neonatal weight in grams, Neonatal length in centimetres, Apgar 1-minute, 5-minute, 10-minute scores in scores, Number of neonatal complications

  5. Incidents of placental insufficiency

    Time frame: up to 6 weeks post-partum

    Incidents of pre-eclampsia, intrauterine growth retardation, placental abruption, and intrauterine foetal death, etc.

  6. Incidents of thrombosis/thromboembolism

    Time frame: From the start of study treatment to 6 weeks post-partum

    thrombosis/thromboembolism

Study contacts

Contact information is provided by the study sponsor or research team.

Meng-Tong Zang, MD

CONTACT

[email protected]

18744579871

Xiao-Hui Zhang, Professor

CONTACT

[email protected]

+8613522338836

Sponsors and collaborators

Lead sponsor

Peking University People's Hospital

Other

Collaborators

  • Beijing Chuiyangliu Hospital
  • Beijing Friendship Hospital
  • Beijing Hospital
  • Beijing Obstetrics and Gynecology Hospital
  • China-Japan Friendship Hospital
  • Chinese PLA General Hospital
  • Peking Union Medical College Hospital
  • Sichuan Academy of Medical Sciences
  • Xiangya Hospital of Central South University

Registry information

Official study title

A Multicenter, Open-label, Randomized, Controlled, Phase 2 Trial Evaluating Whether Low Molecular Heparin Could Improve Pregnancy Outcomes With Protein S Deficiency

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Aug 1, 2024
Registry last updated
Aug 1, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.